Home
About
Help
Alert
Account
Login
Create
Advertisement
Advertisement
Back to Search Results
Search
Advanced
Search
Find article
Advanced search
Evaluation of two secondary prophylaxis regimens of recombinant factor IX (r-IX) in moderately severe to severe (FIX <=2%) hemophilia B patients
Rendo P
;
Barrette-Grischow M-K
;
Smith L
;
Korth-Bradley JM
;
Charnigo R
;
Shafer FE
P. Rendo, Pfizer Inc, Collegeville, PA, United States
Blood. 2012;120((21):): Abstract No. 4628.
Study details
Study Design :
Randomised Controlled Trial